Louise E Lansbury
Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis
Lansbury, Louise E; Rodrigo, Chamira; Leonardi-Bee, Jo; Nguyen-Van-Tam, Jonathan; Shen Lim, Wei
Wei Shen Lim
Objective: Corticosteroids may be beneficial in sepsis but uncertainty remains over their effects in severe influenza. This systematic review updates the current evidence regarding corticosteroids in the treatment of influenza and examines the effect of dose on outcome.
Data Sources: Electronic databases (MEDLINE, EMBASE, CINAHL, LILACS, CENTRAL, Web of Science) and trial registries were searched to October 2018 for randomised controlled trials (RCTs), quasi-experimental designs and observational cohort studies reporting corticosteroid versus no corticosteroid treatment in individuals with influenza.
Study Selection and Data Extraction:
Two researchers independently assessed studies for inclusion. Risk of bias was assessed using the Cochrane Risk of Bias tool (RCTs) or Newcastle-Ottawa Scale (observational studies). Where appropriate, we estimated the effect of corticosteroids by random effects meta-analyses using the generic inverse variance method. Meta‐regression analysis was used to assess the association of corticosteroid dose and mortality.
Data Synthesis: We identified 30 eligible studies, all observational apart from one RCT. Twenty-one observational studies were included in the meta-analysis of mortality, which suggested an adverse association with corticosteroid therapy (Odds ratio (OR) 3.90, 95% confidence interval (CI) 2.31 to 6.60, 15 studies; adjusted hazard ratio 1.49, 95% CI 1.09 to 2.02, 6 studies). Risk of bias assessment was consistent with potential confounding by indication. Pooled analysis of seven studies showed increased odds of hospital-acquired infection in people treated with corticosteroids (unadjusted OR 2.74, 95% CI 1.51 to 4.95).
Meta-regression of the effect of dose on mortality did not reveal an association, but reported doses of corticosteroids in included studies were high (mostly >40 mg methylprednisolone (or equivalent) per day).
Corticosteroid treatment in influenza is associated with increased mortality and hospital-acquired infection, but the evidence relates mainly to high corticosteroid doses and is of low quality with potential confounding by indication a major concern.
|Journal Article Type||Article|
|Publication Date||Feb 1, 2020|
|Journal||Critical Care Medicine|
|Publisher||Lippincott, Williams & Wilkins|
|Peer Reviewed||Peer Reviewed|
|APA6 Citation||Lansbury, L. E., Rodrigo, C., Leonardi-Bee, J., Nguyen-Van-Tam, J., & Shen Lim, W. (2020). Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis. Critical Care Medicine, 48(2), e98-e106. https://doi.org/10.1097/ccm.0000000000004093|
This file is under embargo until Nov 16, 2020 due to copyright restrictions.
You might also like
Influenza in long-term care facilities
Corticosteroids as adjunctive therapy in the treatment of influenza
Co-infections in people with COVID-19: a systematic review and meta-analysis